Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Clinical trial

PharmacOdynaMic Effects of Cangrelor in PatiEnts wIth Acute or chronIc Coronary Syndrome Undergoing Percutaneous Coronary Intervention (POMPEII Registry)

ID
Name
POMPEII Registry
Description
This prospective registry was designed to carefully investigate the pharmacodynamic (PD) effects of cangrelor in all patients undergoing percutaneous coronary intervention (PCI).
Trial arms
Trial start
2021-03-16
Estimated PCD
2024-10-01
Trial end
2024-10-01
Status
Recruiting
Treatment
Cangrelor
All patients receiving Cangrelor during PCI will be enrolled and analyzed for platelet function tests.
Size
100
Primary endpoint
Inhibition of platelet activity (IPA, %) with LTA-ADP 20 µmol/l
30 minutes
Eligibility criteria
Inclusion Criteria: * All adult patients undergoing PCI and receiving cangrelor administration will be eligible for inclusion in the study. Exclusion Criteria: * only those not providing consent to blood/data collection will be excluded.
Protocol
{'studyType': 'OBSERVATIONAL', 'patientRegistry': True, 'targetDuration': '30 Days', 'designInfo': {'observationalModel': 'CASE_ONLY', 'timePerspective': 'PROSPECTIVE'}, 'enrollmentInfo': {'count': 100, 'type': 'ESTIMATED'}}
Updated at
2024-03-05

1 organization

1 product

1 indication

Organization
Federico II University
Product
Cangrelor
Indication
Angioplasty